التفاصيل البيبلوغرافية
| العنوان: |
Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review |
| المؤلفون: |
Salazar, Josefina, Bracchiglione, Javier, Savall-Esteve, Olga, Antequera, Alba, Bottaro-Parra, David, Gutiérrez-Valencia, Marta, Martínez-Peralta, Susana, Pericay, Carles, Tibau, Ariadna, Bonfill, Xavier, Acosta-Dighero, Roberto, Auladell-Rispau, Ariadna, Cantero-Fortiz, Yahveth, Hernandez, Edgar, Irassar, Juan, Meade, Adriana-G, Meinardi, Pamela, Merchán-Galvis, Angela, Meza, Nicolas, Quintana, María Jesús, Requeijo, Carolina, Rodriguez-Grijalva, Gerardo, Salas-Gama, Karla, Santero, Marilina, Selva, Anna, Solà, Ivan, Urrútia, Gerard |
| المساهمون: |
Instituto de Salud Carlos III, European Regional Development Fund |
| المصدر: |
BMC Cancer ; volume 23, issue 1 ; ISSN 1471-2407 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Cancer Research, Genetics, Oncology |
| الوصف: |
Background Patients with advanced pancreatic cancer have a poor prognosis and high burden of cancer-related symptoms. It is necessary to assess the trade-off of clinical benefits and possible harms of treatments with anticancer drugs (TAD). This systematic review aims to compare the effectiveness of TAD versus supportive care or no treatment, considering all patient-important outcomes. Methods We searched PubMed, Embase, Cochrane Library, and Epistemonikos. Two reviewers performed selection, data extraction and risk of bias assessment. We assessed certainty of the evidence using the GRADE approach. Results We included 14 randomised controlled trials. Chemotherapy may result in a slight increase in overall survival (MD: 2.97 months (95%CI 1.23, 4.70)) and fewer hospital days (MD: -6.7 (-8.3, -5.1)), however, the evidence is very uncertain about its effect on symptoms, quality of life, functional status, and adverse events. Targeted/biological therapy may result in little to no difference in overall survival and a slight increment in progression-free survival (HR: 0.83 (95%CI 0.63, 1.10)), but probably results in more adverse events (RR: 5.54 (95%CI 1.24, 23.97)). The evidence is very uncertain about the effect of immunotherapy in overall survival and functional status. Conclusions The evidence is very uncertain about whether the benefits of using treatment with anticancer drugs outweigh their risks for patients with advanced pancreatic cancer. This uncertainty is further highlighted when considering immunotherapy or a second line of chemotherapy and thus, best supportive care would be an appropriate alternative. Future studies should assess their impact on all patient-important outcomes to inform patients in setting their goals of care. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s12885-023-11207-4 |
| DOI: |
10.1186/s12885-023-11207-4.pdf |
| DOI: |
10.1186/s12885-023-11207-4/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s12885-023-11207-4Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.F82D8E5F |
| قاعدة البيانات: |
BASE |
